Recent News

• 03.05.2026 - aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
• 02.20.2026 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2026 - aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
• 02.03.2026 - aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Recent Filings

• 02.25.2026 - 8-K Current report
• 02.25.2026 - EX-99.1 EX-99.1
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 8-K Current report
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2026 - 4 Statement of changes in beneficial ownership of securities